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Abstract Bleeding complications in children may be
caused by disorders of secondary hemostasis or fibrinolysis.
Characteristic features in medical history and physical
examination, especially of hemophilia, are palpable deep
hematomas, bleeding in joints and muscles, and recurrent
bleedings. A detailed medical and family history combined
with a thorough physical examination is essential to
distinguish abnormal from normal bleeding and to decide
whether it is necessary to perform diagnostic laboratory
evaluation. Initial laboratory tests include prothrombin time
and activated partial thromboplastin time. Knowledge of
the classical coagulation cascade with its intrinsic, extrinsic,
and common pathways, is useful to identify potential
defects in the coagulation in order to decide which
additional coagulation tests should be performed.
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Introduction
During their clinical practice, pediatricians will be con-
sulted by parents because of the bleeding symptoms of their
children. It is the task of the pediatricians to decide whether
these bleeding symptoms are “abnormal” and need further
evaluation for the presence of an underlying hemostasis
disorder. Knowledge of the hemostatic physiology and
bleeding disorders is necessary to order proper laboratory
tests and to interpret their results. This review focuses on
the medical history, physical examination, and laboratory
tests, which are important to diagnose disorders of
secondary hemostasis and fibrinolysis. It is the second part
of two contributions on the bleeding child. Diagnosing
primary hemostatic disorders in children has been discussed
previously in this journal [26].
Physiology of secondary hemostasis and fibrinolysis
Hemostasis is a complex process that leads to the formation
of a blood clot at the site of vessel injury. This process is
divided into three components: (a) primary hemostasis,
which starts immediately after endothelial damage and is
characterized by vasoconstriction, platelet adhesion and
aggregation, resulting in the formation of a platelet plug, (b)
secondary hemostasis or coagulation and (c) fibrinolysis
[10].
Secondary hemostasis is defined as the formation of
fibrin through the coagulation cascade. The coagulation
cascade has been classically separated in three pathways:
intrinsic, extrinsic, and common pathways. The intrinsic
pathway involves the contact activation factors (factor XII
[FXII], FXI, high-molecular-weight kininogen [HMWK]
and prekallikrein [PK]), FIX and FVIII. FVIII acts as a
cofactor for the FIXa-mediated activation of FX [5]. The
extrinsic pathway involves the tissue factor (TF) and FVII
complex, which activates FX. Both the intrinsic and
extrinsic pathways come together in the common pathway,
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DOI 10.1007/s00431-011-1571-xwhich involves the FXa-mediated generation of thrombin
from prothrombin and subsequent generation of fibrin from
fibrinogen. Over the past decades, it became clear that the
main pathway for in vivo initiation of coagulation is the
extrinsic, TF-dependent, pathway. Nevertheless, separation
of the cascade into primary, secondary, and common
pathways is very useful to understand the diagnostic
coagulation tests and to identify defects in coagulation
(Fig. 1).
In the current model of coagulation, coagulation is
initiated by the exposure of TF after injury to the
endothelium (Fig. 2). In the initiation phase, TF combines
with activated FVII (FVIIa), which is present at trace levels
in the circulation, to form the TF-FVIIa complex [8]. This
complex activates FX and FIX. Activated FX can catalyze
the conversion of prothrombin (FII) into thrombin (FIIa).
The amount of thrombin generated by this initiation step is
very small and insufficient to produce an adequate amount
of fibrin to stabilize the platelet plug. However, in the
amplification phase, thrombin also activates platelets,
causing changes in phospholipid asymmetry resulting in the
assemblyofcoagulationfactorsontheplateletmembrane,and
release of granule contents including FV. Furthermore,
thrombin activates FV, FVIII, and FXI. Activation of factor
VIII by thrombin results in dissociation of FVIII from its
carrier protein von Willebrand factor (VWF). Cofactor FVIIIa
together with the initial FIXa formed by the TF-FVIIa
complex, activate factor X, which forms a protected complex
with its cofactor FVa. This FIXa is supplemented by factor
IXa generated on the platelet surface by factor XIa. The FXa/
Va complex generates a burst of thrombin, which is required
for the formation of a stable fibrin clot [17]. Finally, thrombin
prevents early removal of the clot by the fibrinolytic system
by activating FXIII, which is not only responsible for
crosslinking of soluble fibrin monomers into an insoluble
fibrin matrix, but also for incorporating α2-antiplasmin into a
forming clot to protect against premature degradation by
fibrinolytic proteases [7].
Endogenous anticoagulants inhibit coagulation and
prevent thrombosis. The most important inhibitors are
Fig. 1 The classical coagulation model: two pathways, intrinsic and
extrinsic, come together in the common pathway at the level of factor
X (FX). This model is useful for interpretation results of the core
coagulation tests prothrombin time (PT) and activated partial
thromboplastin time (APTT)
208 Eur J Pediatr (2012) 171:207–214antithrombin, protein C, and protein S. Antithrombin
inactivates several activated coagulation factors, including
thrombin, FXa, FIXa, and FXIa. Protein C is activated by
thrombin after binding of thrombin to the protein thrombo-
modulin on the surface of endothelial cells. Together with
its cofactor protein S, activated protein C effectively
degrades FVa and FVIIIa, thus limiting further coagulation.
Patients with deficiencies of antithrombin, protein C, and
protein S have an increased risk for thromboembolic
complications.
Fibrinolysis is the process wherein the fibrin clot is
broken down into its degradation products. Plasmin is the
central enzyme of the fibrinolytic system. An important
activator of plasmin is tissue plasminogen activator (t-PA)
that converts plasminogen into plasmin. Inhibitors of the
fibrinolysis include plasminogen activator inhibitor (PAI)
and α2-antiplasmin. Deficiencies of PAI and α2-antiplasmin
result in increased fibrinolysis which may cause bleeding.
Disorders of secondary hemostasis and fibrinolysis
Hemophilia A and B
Hemophilia A and B are the most common inherited
coagulation disorders, respectively resulting from a defi-
ciency of coagulation factors VIII and IX. Both factors are
crucial for normal generation of thrombin. Hemophilia is an
X-linked disorder. About one third of the patients do not have
a positive family history as about 30% of the mutations occur
de novo. The worldwide incidence of hemophilia A is
approximately 1 per 5,000 male individuals. Hemophilia B
is present in 1 per 30,000 male individuals [14, 21]. The
clinical severity of the disorder is related to the level of FVIII
and IX. Severe hemophilia is characterized by a clotting
factor level of less than 1%. In moderate hemophilia, the
FVIII or IX level is between 1% and 5%. Mild hemophilia
patients have a factor level between 6% and 40%.
The key manifestations of patients with severe hemophilia
are muscle and joint hemorrhages, which may occur sponta-
neously or after mild trauma. Recurrent joint bleeds will lead
to irreversible joint damage (hemophilia arthropathy). In
patients with mild and moderate hemophilia, hemorrhages
generally do not occur spontaneously. Treatment of bleeding
episodes consists of administering recombinant or plasma-
derived clotting factor VIII or IX concentrates. To prevent
joint bleedings and thus arthropathy in patients with severe
hemophilia, prophylactic treatment with clotting factor con-
centrate is mostly indicated [13].
Factor XI deficiency
FXI deficiency was discovered in 1953 by Rosenthal [23].
It is a very rare bleeding disorder with an estimated
Fig. 2 The current model of coagulation and fibrinolysis.
Initiation phase: after endothelium injury tissue, tissue factor
(TF) forms a complex with activated factor VII (FVIIa) that activates
FIX and FX. FXa converts prothrombin (FII) in thrombin (FIIa). In
the amplification phase, thrombin activates FV, FVIII and FXI. FIXa
binds to FVIIIa, activating FX. FXa binds to FVa, leading to an
increased rate of prothrombin conversion to thrombin, finally
converting fibrinogen into fibrin, which is stabilized by FXIIIa.
Tissue-plasminogen activator (t-PA) converts plasminogen into
plasmin that breaks down the fibrin clot into its fibrin degradation
products (FDPs). Plasminogen activator inhibitor-1 (PAI-1) and
α2-antiplasmin inhibit fibrinolysis
Eur J Pediatr (2012) 171:207–214 209incidence of one per million. In contrast to the incidence in
the general population, congenital FXI deficiency is
particularly common among the Ashkenazi Jewish popula-
tion with a carrier rate up to 8% [3]. The inheritance pattern
of FXI deficiency is autosomal recessive. The autosomal
recessive pattern is misleading because carriers can also
have bleeding symptoms. The bleeding tendency of patients
with a FXI deficiency is highly variable and unpredictable.
The FXI level does not correlate with the severity of the
deficiency as in contrast to patients with hemophilia A and
B. Bleeding episodes occur predominantly after trauma or
surgery in tissue with high fibrinolytic activity (e.g.,
urogenital tract, oral cavity, or nasopharyngeal area).
Women with FXI deficiency are prone for menorrhagia.
Spontaneous joint or muscle hemorrhages are not observed
in this patient group. Treatment of bleeding episodes
consists of administrating plasma or FXI concentrates and
anti-fibrinolytic drugs [2].
Other congenital bleeding disorders
All the other congenital bleeding disorders are extremely
rare. Table 1 shows the incidence rate, inheritance pattern,
clinical manifestations, and treatment modalities of these
coagulation disorders [4].
Acquired coagulation disorders
Acquired coagulation disorders in sick children are more
common than congenital coagulation disorders. Vitamin K
deficiency is probably the most frequent bleeding disorder
of childhood, which can lead to life-threatening bleeding
[25]. It may be the result of inadequate intake or
malabsorption in children with gastrointestinal diseases
including cystic fibrosis, α1-antitrypsin deficiency, and
biliary atresia. Vitamin K deficiency causes decreased
production of the vitamin K-dependent coagulation factors
II, VII, IX, and X but also anticoagulant proteins protein C
and protein S. Vitamin K is an essential cofactor in the
carboxylation of glutamate to γ-carboxyglutamate residues,
allowing calcium binding and so activating the vitamin
K-dependent proteins. In the blood of vitamin K-deficient
patients, undercarboxylated forms of vitamin K-dependent
coagulation proteins (proteins induced by vitamin K
absence) can be found [27]. Disseminated intravascular
coagulation (DIC) is caused by several disorders, including
sepsis, malignancy, and hypoxia. It is characterized by a
systemic activation of the blood coagulation system, which
results in the generation and deposition of fibrin, leading to
micro-vascular thrombi and contributing to the develop-
ment of multi-organ failure. Consumption of coagulation
Table 1 Incidence, inheritance, clinical manifestations, and therapeutic modalities, for both the congenital coagulation factor deficiencies and the
fibrinolytic defects [4, 6, 15]
Incidence Inheritance Clinical manifestations Therapeutic modalities
Congenital coagulation factor deficiencies
Hypo-, or afibrinogenemia
(FI deficiency)
1 per 1,000,000 AR Bleeding of umbilical cord, in gastro-intestinal tract,
in genito-urinary tract, in CNS,
posttraumatic/post-surgery bleeding, mucocutaneous
bleeding or joint bleeding (rare)
Pd-fibrinogen conc.Plasma
FII deficiency
(prothrombin deficiency)
1 per 2,000,000 AR Bleeding of muscle or joint, mucocutaneous bleeding,
or CNS bleeding (rare)
Prothrombin complex conc.
Plasma
FV deficiency 1 per 1,000,000 AR Mucocutaneous bleeding, joint bleeding (rare) or umbilical
cord bleeding (rare)
Plasma
FVII deficiency 1 per 500,000 AR Bleeding of joint, CNS bleeding or mucocutaneous bleeding Pd-FVII conc.Rec. FVIIa
conc.
FVIII deficiency
(hemophilia A)
1 per 5,000 males X-linked Bleeding of joint or muscle, in CNS, posttraumatic/
post-surgery bleeding or mucocutaneous bleeding
Rec. FVIII conc.Pd-FVIII
conc.
FIX deficiency
(hemophilia B)
1 per 30,000 males X-linked Bleeding of joint or muscle, in CNS, posttraumatic/
post-surgery bleeding or mucocutaneous bleeding
Rec. FIX conc.Pd-FIX
conc.
FX deficiency 1 per 1,000,000 AR Mucocutaneous bleeding, posttraumatic/post-surgery bleeding,
umbilical cord or joint bleeding (rare)
Prothrombin complex conc.
Plasma
FXI deficiency
(hemophilia C)
1 per 1,000,000 AR Posttraumatic bleeding/post-surgery bleeding, mucocutaneous
bleeding
Pd-FXI conc.Plasma
FXII deficiency 25 per 1,000 AR None Not necessary
FXIII deficiency 1 per 1,000,000 AR Bleeding of umbilical cord or in CNS, poor wound healing Pd-FXIII conc. or plasma
Congenital fibrinolytic defects
Antiplasmin deficiency Rare AR Mucocutaneous bleeding, posttraumatic/post-surgery re-bleeding,
bleeding of joint, umbilical cord or in CNS
Antifibrinolytic
drugsPlasma
Plasminogen activator
inhibitor 1 deficiency
Rare AR Mucocutaneous bleeding, posttraumatic/post-surgery re-bleeding,
bleeding of joint or in CNS
Antifibrinolytic drugs
FV factor V, AR autosomal recessive, CNS central nervous system, conc. concentrate, Pd plasma-derived, rec. recombinant
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tions [12]. Finally, children with severe liver disease have
deficiencies of almost all coagulation factors, which results
in increased risk of bleeding.
Medical history and physical examination
Medical history and physical examination are important
tools to decide whether it is necessary to perform laboratory
testing for one of the above-discussed hemostasis disorders.
In general, there is suspicion of an underlying bleeding
disorder whenever the duration of the bleeding is longer
and the quantity higher than one would expect. Information
about the type and pattern of bleeding may help to
distinguish secondary from primary bleeding disorders.
Bleedings into soft tissue, muscles and joints, and recurrent
bleedings are indicative for a secondary hemostasis prob-
lem in contrast to mucocutaneous bleeding symptoms and
persistent bleedings, which are more suggestive for primary
hemostasis disorders.
The time of onset of the bleeding symptoms can be
informative about the cause of the bleedings and the
severity of the bleeding disorder. Signs and symptoms of
acquired disorders typically develop over a period of days
to weeks. Symptoms of congenital disorders usually exist
for a long time. To obtain information about previous
bleeding symptoms, it is essential to ask accurately about
the past, particularly about potential challenges of the
hemostatic system, including birth, heel prick, shedding of
the umbilical stump, immunizations, the time when the
child started to become mobile, surgical and dental
interventions, trauma, and menstruation. Umbilical bleed-
ing, for example, is frequently (80%) seen in patients with
FXIII deficiency. Severe congenital coagulation disorders
usually present early in life, whereas mild disorders become
apparent later in childhood or even in adulthood.
Furthermore, family history is crucial in the quest for
congenital coagulation disorder, especially in young chil-
dren, who had not yet experienced challenges to their
hemostatic system.
Knowledge of concomitant illnesses and medication is
indispensable to find the cause of bleedings. Malabsorption
may lead to impaired vitamin K absorption. Severe liver
disease and/or DIC cause impaired production or concen-
tration of almost all coagulation factors. Vitamin K
antagonists, including warfarin and acenocoumarol, prevent
carboxylation of the vitamin-dependent coagulation factors,
making them ineffective, and over-anticoagulation may
result in severe bleeding complications [1].
Signs for secondary hemostasis disorders in physical
examination are palpable deep hematomas, joint or intra-
muscular bleeds, especially in hemophilia. Abnormal scar
formation can be present in patients with FXIII deficiency.
Finally, always keep child abuse in mind while evaluating a
child with bleeding complications.
Laboratory evaluation
Based on medical and family history and physical exam-
ination, the pediatrician decides to perform laboratory
testing for disorders of secondary hemostasis and fibrinolysis.
The first-step screening tests are the prothrombin time (PT)
and the activated partial thomboplastin time (APTT). There
are several techniques, including clot-based assays and
chromogenic or color assays, to test coagulation. The end
point of clot-based assays is fibrin clot formation, whereas the
generation of thrombin is that of chromogenic assays. In
general, the PT and APTT are clotting assays. As a result of
various assays and reagents used, each laboratory has its own
normal values ranges.
Prothrombin time
The PT clotting assay was introduced by Armand Quick in
1935 [19]. PT represents the time in seconds, required for
clot formation after the addition of thromboplastin
(a combination of TF and phospholipids) and calcium to
citrated plasma [20]. It evaluates the integrity of the
extrinsic and common pathways of the coagulation cascade.
The PT reagents have a variable sensitivity to different
coagulation factors. For instance, PT reagents are more
sensitive to deficiencies of FVII than to deficiencies of the
common pathway. Deficiencies of coagulation factors
within the extrinsic and common pathways may prolong
the PT, including FVII, FX, FV, FII, and fibrinogen (Fig. 1).
PT is normal in patients with a-, hypo- or dysfibrinogene-
mia using a chromogenic assay, as the end point of this test
is the generation of thrombin instead of a fibrin clot.
Activated partial thromboplastin time
This screening test was introduced by Langdell and has
been used since the 1850s as a screening test [11]. The
APTT clotting assay evaluates the integrity of the intrinsic
and common pathways. The test is performed by adding a
“partial thromboplastin” reagent (phospholipids without
TF) to the patient's citrated plasma. To introduce controlled
activation of the contact factors, incubation with a surface
contact activator (such as celite, kaolin, silica, or ellagic
acid) must take place. Hereafter, calcium chloride is added
and the time in seconds required for clot formation is
recorded. Deficiencies of coagulation factors of the intrinsic
(HMWK, PK, FXII, FXI, FIX, FVIII) and common path-
ways (X, V, II, and fibrinogen) result in prolongation of the
Eur J Pediatr (2012) 171:207–214 211APTT (Fig. 1)[ 20]. As for the PT reagents, the APTT
reagents have various sensitivities to different clotting
factors. Furthermore, APTT is normal in patients with
a-, hypo- or dysfibrinogenemia using a chromogenic APTT
assay, as the end point of this test is the generation of
thrombin instead of a fibrin clot.
Interpretation of laboratory results
A prolonged PT and/or APTT should be further evaluated.
It is important to realize that several factors may influence
the accuracy of the tests. The tubes should be correctly
filled; otherwise, the ratio of blood to anticoagulant (3.2%
trisodium citrate) will change. The anticoagulant in the
collection tubes prevents activation of the coagulation by
chelating calcium. The ratio of whole blood to anticoagu-
lant should be 9:1 in patients with hematocrits of 35–50%.
Underfilling of the tubes, as well as high hematocrit, will
result in falsely high results. A clot in the tube will lead to
consumption of coagulation factors and cause prolongation
of the PT and APTT. Furthermore, contamination with
heparin may occur when the blood is drawn from a central
venous catheter, leading to prolongation of APTT. In other
words, before ordering further laboratory tests to investigate
the prolongation of PT and/or APTT, clinicians should
consider to repeat the screening tests to exclude false
results.
Prolonged PT with normal APTT
An isolated prolongation of the PT indicates an acquired or
congenital FVII deficiency (Fig. 3). As the incidence of
congenital FVII deficiency is very low, an acquired
deficiency of FVII should be considered first. FVII is one
of the vitamin K-dependent coagulation factors and has the
shortest half-life. In mild vitamin K deficiency, FVII levels
drop first, causing prolongation of PT. The diagnosis is
confirmed if the PT normalizes after administration of
vitamin K. If prolongation of PT persists in spite of extra
vitamin K, a congenital factor VII deficiency must be
considered [18]. Administration of vitamin K antagonists
causes an isolated PT prolongation as well. The PT is used
Fig. 3 Approach to children with bleeding symptoms and normal or
prolonged prothrombin time (PT) or activated partial thromboplastin
time (APTT). def deficiency, vit. vitamin, VWD von Willebrand
disease, DIC disseminated intravascular coagulation, PAI1 plasmino-
gen activator inhibitor I, VWF Ag von Willebrand factor antigen, RCo
ristocetin cofactor, LAC lupus anticoagulans, TT thrombin time, PK
prekallikrein, HMWK high-molecular-weight kininogen, INR interna-
tional normalized ratio, VKA vitamin K antagonist, F factor
212 Eur J Pediatr (2012) 171:207–214to monitor the effect of this anticoagulant therapy. As a
result of the various sensitivities of PT reagents, a
standardized method of expressing the prolongation of PT
as an international normalized ratio has been developed [1].
Prolonged APTT with a normal PT
Isolated prolongation of the APTT can be caused by
congenital factor deficiencies of the intrinsic pathway
(FVIII, FIX, FXI, FXII, HMWK, or PK). Specific clotting
factor assays can be performed to identify the deficient
coagulation factor. FVIII (hemophilia A), FIX (hemophilia
B), and FXI deficiencies are associated with bleeding
complications in contrast to deficiencies of FXII, HMWK,
and PK. As HMWK and PK deficiencies are extremely
rare, assays for these deficiencies are not commonly
performed. Acquired causes of prolonged APTT with
normal PT are heparin therapy, the presence of inhibitors
directed against specific coagulation factors and the
presence of nonspecific inhibitors (e.g., lupus anticoagulans
[LAC]), which are antibodies directed against phospholi-
pids. A mixing test can be performed to differentiate
between coagulation factor deficiencies or the presence of
heparin or an inhibitor. In a mixing test, prolonged APTT
plasma is mixed with normal plasma in equal proportions.
Normalization of the APTT following mixing indicates a
factor deficiency. Plasma FVIII levels can be low in both
hemophilia A patients and von Willebrand disease (VWD)
patients, as one of the functions of VWF is binding and
stabilizing FVIII in the circulation. Persistent prolongation
of the APTT after a mixing test is indicative for the
presence of heparin, a specific coagulation factor inhibitor
or LAC. A LAC test or specific factor inhibitor tests can be
performed to confirm the diagnosis of a coagulation factor
inhibitor. The presence of heparin causes prolongation of
the thrombin time (TT). The TT evaluates the final step of
the coagulation cascade, the conversion of fibrinogen to
fibrin and is performed by adding thrombin to citrated
plasma. Prolongation of TT is also present in patients with
DIC as result of increased fibrin degradation products
(FDPs) and in patients with fibrinogen disorders.
Prolonged PT and prolonged APTT
Prolongation of both PT and APTT can be caused by
isolated congenital coagulation factor deficiencies of the
common pathway: fibrinogen, FII, FV or FX, or a
qualitative defect of fibrinogen (dysfibrinogenemia)
(Fig. 1). A-, hypo-, or dysfibrinogenemia should be
considered if in addition to PT and APTT, TT is abnormal.
All these defects are very rare (Table 1). Combined
congenital FV and FVIII deficiency causes prolongation
of PT and APTT, as well. This is a very rare, autosomal
recessive, mild bleeding disorder caused by mutations in
genes encoding proteins involved in the FV and FVIII
intracellular transport (LMAN1 and MCFD2) [24]. More
frequently, PT and APTT are prolonged as result of
acquired factor deficiencies in patients with liver dysfunc-
tion, severe vitamin K deficiency, DIC, or supratherapeutic
dosages of vitamin K antagonists or heparin. Vitamin K
deficiency is the most frequent cause. It is characterized by
deficiencies of the vitamin K-dependent factors only,
whereas in DIC and liver dysfunction, plasma levels of
almost all coagulation factors are decreased. In contrast to
DIC, vitamin K deficiency is usually not accompanied by
thrombocytopenia. Thrombocytopenia may occur in liver
disease, as well, due to portal hypertension or splenomeg-
aly. DIC is associated with increased plasma levels of fibrin
D-dimer, one of the major FDPs. In neonates, mild
prolongation of both PT and APTT is always present as a
result of physiologically low levels of vitamin K-dependent
clotting factors after birth. These reach adult values by
6 months of age [16].
Normal PT and APTT
Children with a strong positive bleeding history and normal
PT and APTT results should be tested for FXIII deficiency
(Fig. 1). Other defects, which are not detectable with
routine coagulation screening tests, are vitamin C deficien-
cy and extremely rare fibrinolytic disorders, e.g., α2
−antiplasmin and PAI deficiency. (Table 1) Vitamin C
deficiency results in impaired collagen synthesis. Present-
ing signs and symptoms are mucosal bleeding, petechiae,
and ecchymoses [22]. Finally, normal PT and APTT results
do not exclude mild deficiencies of coagulation factors,
including FVIII and FIX. It is important to realize that the
results of the screening tests depend on the sensitivity of the
used assay system and reagents, which vary among
hospitals. Furthermore, mild deficiencies might remain
undetected as result of elevated levels of other coagulation
deficiencies, including FVIII. Therefore, if suspicion of a
coagulation disorder is high, mild hemophilia A and B and
VWD must be excluded as well as factor XIII deficiency,
fibrinolytic disorders, and vitamin C deficiency [9].
Summary
Medical and family history and physical examination are
important tools to decide whether children with an
increased bleeding tendency need diagnostic laboratory
evaluation. Initial screening tests for disorders of secondary
hemostasis include PT and APTT. Disorders of fibrinolysis
are rare. Knowledge of the classical coagulation cascade
with its intrinsic, extrinsic, and common pathways, is useful
Eur J Pediatr (2012) 171:207–214 213to identify potential defects in the coagulation and to decide
which additional coagulation tests should be performed.
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